Sign inJoin waitlistJoin the waitlist

Orrin Troum

Physician · Providence Southern California

Credentials: · · · ·

History

Providence Southern California
Present

Rheumatology
University of Southern California/Los Angeles General Medical Center
1982–1984
Internal Medicine
University of Southern California/Los Angeles General Medical Center
1979–1982
UNIV AUTO DE GUADALAJARA, FAC DE MED, GUADALAJARA, JALISCO, MEXICO
1975–1979

Research

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Annals of the Rheumatic Diseases · 2014 · 119 citations
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Annals of the Rheumatic Diseases · 2007 · Last of 20 authors · 90 citations
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
Annals of the Rheumatic Diseases · 2015 · 86 citations

CP
Charles Peterfy
5 papers
EO
Ewa Olech
5 papers
AW
Alvin Wells
4 papers
JC
John Crues
4 papers
Veena Ranganath
4 papers
BL
Brian LaMoreaux
3 papers
NG
Norman Gaylis
3 papers
VS
Vibeke Strand
3 papers
Arthur Kavanaugh
2 papers
AD
Atul Deodhar
2 papers
Daniel Furst
2 papers
Eric Ruderman
2 papers

Clinical trials

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects
Principal investigator · Completed
Orrin M Troum, M.D. and Medical Associates
2011–2012
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
Principal investigator · Completed · Phase 2, Phase 3
Orrin M Troum, M.D. and Medical Associates
2011–2014
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
Site PI · Unknown
Ampel BioSolutions, LLC
2023–2025